N/Aintellectual_propertypharmaceutical
Criticism of IPO’s 2026 Draft Pharmaceutical Patent Guidelines
The IPO’s 2026 Draft Guidelines face strong critique for misquoting law and risking disruption to patent prosecution in pharmaceuticals; calls grow for immediate revision.
Sep 30, 2026Read more →